Profile data is unavailable for this security.
About the company
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
- Revenue in USD (TTM)1.53m
- Net income in USD-37.13m
- Incorporated1999
- Employees33.00
- LocationLumos Pharma Inc4200 MARATHON BLVD., SUITE 200AUSTIN 78756United StatesUSA
- Phone+1 (512) 215-2630
- Fax+1 (515) 296-3520
- Websitehttps://lumos-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIM ImmunoTech Inc | 202.00k | -28.96m | 19.85m | 26.00 | -- | 2.01 | -- | 98.25 | -0.595 | -0.595 | 0.0042 | 0.2084 | 0.0068 | -- | 0.1413 | 7,769.23 | -96.75 | -45.64 | -116.18 | -48.35 | 79.21 | -231.75 | -14,337.62 | -11,695.01 | -- | -- | 0.00 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| Evaxion Biotech A/S - ADR | 73.00k | -22.13m | 19.97m | 49.00 | -- | -- | -- | 273.61 | -81.29 | -81.29 | 0.2665 | -1.25 | 0.0042 | -- | 0.091 | 1,489.80 | -126.74 | -100.11 | -183.85 | -131.65 | -- | -- | -30,308.22 | -131,560.30 | -- | -30.92 | 1.77 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| Cocrystal Pharma Inc | 0.00 | -17.98m | 19.99m | 12.00 | -- | 0.7577 | -- | -- | -1.90 | -1.90 | 0.00 | 2.59 | 0.00 | -- | -- | 0.00 | -49.89 | -50.94 | -53.19 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.98m | 20.49m | 7.00 | -- | 2.19 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Nymox Pharmaceutical Corp | 0.00 | -4.87m | 20.51m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.55m | -27.24m | 20.59m | 36.00 | -- | 0.5329 | -- | 13.25 | -1.02 | -1.02 | 0.0574 | 1.39 | 0.0338 | -- | 0.3774 | 43,166.67 | -59.27 | -31.60 | -64.80 | -35.49 | -- | -- | -1,752.77 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 21.15m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -40.16m | 21.26m | 42.00 | -- | 1.37 | -- | -- | -1.89 | -1.89 | 0.00 | 0.5242 | 0.00 | -- | -- | 0.00 | -103.63 | -- | -128.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 38.83m | -8.42m | 21.29m | 91.00 | -- | 0.7727 | -- | 0.5483 | -0.596 | -0.596 | 2.72 | 1.94 | 0.4542 | 0.8812 | 3.08 | 426,654.70 | -9.83 | -7.03 | -14.07 | -9.52 | 83.54 | 79.95 | -21.65 | -17.64 | 1.21 | -37.10 | 0.3717 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Polypid Ltd | 0.00 | -24.25m | 21.30m | 59.00 | -- | 2.98 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Lumos Pharma Inc | 1.53m | -37.13m | 21.35m | 33.00 | -- | 1.22 | -- | 14.00 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | -- | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Bioxytran Inc | 0.00 | -4.30m | 21.70m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 22.41m | 109.00 | -- | 0.2892 | -- | 13.34 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 22.57m | 8.00 | -- | 2.24 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Zivo Bioscience Inc | 63.37k | -7.08m | 22.60m | 8.00 | -- | -- | -- | 356.62 | -3.83 | -3.83 | 0.0318 | -0.8133 | 0.0652 | -- | -- | 7,921.25 | -728.52 | -376.60 | -- | -- | 38.05 | -- | -11,176.47 | -96,315.32 | -- | -88.46 | -- | -- | -- | -- | 11.07 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 22.77m | 4.00 | -- | 3.35 | -- | 350.26 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to Lumos Pharma Inc's reporting currency: US Dollar USD
22.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 415.51k | 5.13% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 406.61k | 5.02% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 244.08k | 3.01% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 221.61k | 2.73% |
| Acuitas Investments LLCas of 31 Mar 2024 | 140.69k | 1.74% |
| Jefferies Investment Advisers LLCas of 31 Dec 2023 | 120.65k | 1.49% |
| Lion Point Capital LPas of 31 Dec 2023 | 90.79k | 1.12% |
| Greenwich Wealth Management LLCas of 31 Dec 2023 | 76.34k | 0.94% |
| Bridgeway Capital Management LLCas of 31 Dec 2023 | 47.64k | 0.59% |
| Geode Capital Management LLCas of 31 Dec 2023 | 47.60k | 0.59% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
